摘要
目的:探讨何氏养肾方治疗2~3期慢性肾病(chronic kidney disease,CKD)的疗效。方法:将150例CKD患者随机分为3个组各50例,在基础治疗基础上,对照组采用盐酸贝那普利治疗,治疗1组采用何氏养肾方治疗,治疗2组采用贝那普利联合何氏养肾方治疗,比较3个组肾功能指标、24 h尿蛋白定量(24 h UP)变化、临床疗效、治疗前后中医证候积分及安全性。结果:治疗2组24 h UP减少(P<0.05)且低于对照组与治疗1组(P<0.05);治疗2组总有效率高于对照组与治疗1组(P<0.05);治疗后,3个组中医证候积分均降低,但治疗2组降低的更为明显(P<0.05)。结论:何氏养肾方与贝那普利联用治疗CKD(2~3期)安全有效。
Objective ：To investigate the effect of Heshiyangshen prescription in the treatment of 2 - 3 stage chronic kidney disease （CKD）. Methods ：150 cases of patients with CKD were randomly divided into three groups, 50 cases in each group. On the basis of basic treatment, the control group was treated with Benazepril Hydroehloride Tablets, the treatment group 1 was treated with He^hiyangshen prescription, and the treatment group 2 was treated with Benazepril Hydrochloride Tablets and Heshiyangsben prescription. The renal function indexes, changes of 24h urinary protein （24 hUP） , clinical efficacy, TCM syndrome score before and after treatment and safety were compared in the three groups. Results：The 24 hUP in the treatment group 2 decreased significantly （ P 〈 0.05 ）, and was significantly lower than that of the control group and treatment group 1 （ P 〈 0.05 ）. The total effective rate in the treatment group 2 was significantly higher than those of the cortrol group and the treatment group 1 （ P 〈 0.05 ） . After treatment, the scores of TCM syndromes decreased in the three groups, and the reduction in the treatment group 2 was more significant （ P 〈 0.05 ）. Conclusion： Heshiyangshen prescription in the treatment of CKD （2 -3 stage） is safe and effective, worthy of clinical recommendation.
出处
《包头医学院学报》
CAS
2017年第11期114-116,共3页
Journal of Baotou Medical College
基金
东莞市科技局项目(2015108101021)
省中医药管理局项目(20151120)
关键词
何氏养肾方
慢性肾脏病
肾功能
疗效
Heshiyangshen prescription
Chronic kidney disease
Renal function
Curative effect
